Prothena
Prothena

Prothena

Biotechnology
WebsiteInvestor RelationsSEC
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

$455.9M

Market Cap • 9/11/2026

2012

(14 years)

Founded

2012

(14 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,6

P/S

8,4

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

5,4

EPS

—

Market Cap

Market Cap

455,9M

EV

174,7M

EV/Revenue

3,2

EV/EBITDA

-3,2

EV/EBIT

-3,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

4,9%

Total Yield

4,9%

Payout

0%

Retained Earnings

-1,3B

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

119,1%

Capex/Revenue

1,2%

Capex/D&A

80%

Capex/OCF

-1,1%

SBC/OCF

—

% PPE

3%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-2,1%

CAGR Op. Income 5Y

-3,2%

CAGR Net Income 5Y

-9%

CAGR EPS 5Y

-14,8%

CAGR OCF 5Y

11,1%

Leverage

N.D./EBITDA

5,1

Debt/Equity

0%

Current Ratio

25

Quick Ratio

24,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium